Ablynx signs exclusive Nanobody deal with Wyeth; terminated
Ablynx (therapeutic antibodies) licensed Wyeth Pharmaceuticals exclusive global rights to develop and commercialize Nanobodies targeting the tumor necrosis factor alpha protein and its receptors for use in treating various diseases such as rheumatoid arthritis.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com